Pharma Stability: Insights, Guidelines, and Expertise
Accelerated stability testing involves subjecting pharmaceutical products to elevated stress conditions—usually high temperature and humidity—for a defined period. This simulates long-term degradation in a short time and is useful for:
Click to read the full article.
The International Conference on Harmonisation (ICH) introduced the Common Technical Document (CTD) format to harmonize submissions. Stability data is primarily housed in:
Click to read the full article.
Background: A mid-sized generic manufacturer submitted a product registration dossier to the Thai FDA. The product was intended for sale across ASEAN nations, including Vietnam, Indonesia, and the Philippines.
Click to read the full article.
Regulatory authorities define stability conditions based on climatic zones that reflect temperature and humidity extremes in a region. Understanding these zones is the first step in harmonization:
Click to read the full article.
The ICH Q1A guideline establishes principles for stability testing of new drug substances and products. Key elements include:
Click to read the full article.
Each region interprets and enforces stability requirements differently:
Click to read the full article.
Both the FDA and the Therapeutic Goods Administration (TGA) in Australia use the ICH Q1B guideline as the backbone of photostability testing. However, real-world execution often varies based on regulatory culture, emphasis areas, and inspection history.
Click to read the full article.
The ACTD framework is used in the following countries: Indonesia, Malaysia, Philippines, Singapore, Thailand, Vietnam, Brunei, Cambodia, Laos, and Myanmar. Although the structure of the ACTD is unified, national authorities still retain the right to interpret and enforce labeling rules based on their jurisdictional policies.
Click to read the full article.
Bridging studies allow pharmaceutical companies to leverage existing stability data from one region or formulation to support regulatory filings in other markets. Bridging is especially useful when:
Click to read the full article.
Lifecycle management of stability submissions involves the ongoing generation and reporting of stability data throughout the life of a pharmaceutical product. Key phases include:
Click to read the full article.